Jon Pilcher interviewed by Stephen Mayne from Intelligent Investor
Jon Pilcher sat down with Stephen Mayne from Intelligent Investor to talk through where things stand for Neuren - from the EU regulatory turnaround for DAYBU® to how the company is funding the next chapter of its pipeline.
Neuren Pharmaceuticals: The Next Chapter - Intelligent Investor
Note: This content is hosted on Intelligent Investor and access is subject to their platform policies.
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Neuren Pharmaceuticals. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Neuren Pharmaceuticals a question about this update.